Skip to main content
CNTX
NASDAQ Life Sciences

Context公司的CTIM-76部分反应被报告，关键里程碑即将到来；现金跑道延伸至2027年中期

feedReported by Wiseek News
Sentiment info
Positive
Importance info
8
Price
$3.02
Mkt Cap
$277.475M
52W Low
$0.49
52W High
$3.62
Market data snapshot near publication time

summarizeSummary

Context Therapeutics已经更新了其公司介绍，披露了其正在进行的1a期试验中CTIM-76报告的部分反应。这一积极的临床信号对于公司的首要肿瘤学候选药物具有重要意义。更新还标志着即将到来的CTIM-76的中期1a期数据（于2026年6月）和CT-95的中期数据（于2026年9月），以及预计2026年第三季度CT-202的首位患者参加1期试验。关键的是，公司确认了现金跑道延伸至2027年中期，为推进其产品线提供了财务稳定性。这些临床发展和财务清晰度对于小盘生物科技公司具有重要意义，提供了2026年和2027年多个潜在的催化剂。

在该公告发布时，CNTX的交易价格为$3.02，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2.8亿。 52周交易区间为$0.49至$3.62。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed CNTX - Latest Insights

CNTX
Apr 28, 2026, 4:12 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on 100 Million Share Increase, Enabling Over 100% Potential Dilution
Sentiment: Negative
View Wiseek Article
CNTX
Apr 17, 2026, 4:29 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Context Therapeutics Seeks Shareholder Approval to Double Authorized Common Stock
Sentiment: Negative
View Wiseek Article
CNTX
Apr 02, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
8
Context Therapeutics' CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
Sentiment: Positive
View Wiseek Article
CNTX
Apr 02, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Partial Response Reported for Context's CTIM-76, Key Milestones Ahead; Cash Runway into Mid-2027
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
8
Context Therapeutics Reports Partial Response in CTIM-76 Phase 1a Trial, Extends Cash Runway
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:09 PM EDT
Filing Type: 10-K
Importance Score:
8
Context Therapeutics Reports Increased Losses, $75M ATM Program, and Over 100% Potential Dilution
Sentiment: Negative
View Wiseek Article
CNTX
Mar 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Court Approves Governance Changes, Eliminating Staggered Board and 'For Cause' Director Removal
Sentiment: Positive
View Wiseek Article
CNTX
Feb 27, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Context Therapeutics to Adopt Annual Director Elections, Resolving Shareholder Lawsuit
Sentiment: Positive
View Wiseek Article
CNTX
Jan 08, 2026, 7:43 AM EST
Filing Type: 8-K
Importance Score:
8
Context Therapeutics Reports Positive Interim Phase 1a Data for CTIM-76 and Extends Cash Runway
Sentiment: Positive
View Wiseek Article